Cargando…

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice

Minimal residual disease (MRD) in non-Hodgkin's lymphomas (NHLs) still represents matter of interest and debate: indeed, the new available treatments offer higher rates of complete responses and MRD negativity than in the past, with a positive impact on the long-term survival. Furthermore, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galimberti, Sara, Genuardi, Elisa, Mazziotta, Francesco, Iovino, Lorenzo, Morabito, Fortunato, Grassi, Susanna, Ciabatti, Elena, Guerrini, Francesca, Petrini, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606710/ https://www.ncbi.nlm.nih.gov/pubmed/31293969 http://dx.doi.org/10.3389/fonc.2019.00528

Ejemplares similares

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
por: Galimberti, Sara, et al.
Publicado: (2017)

The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients
por: Salehzadeh, Serena, et al.
Publicado: (2019)

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
por: Grassi, Susanna, et al.
Publicado: (2019)

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
por: Mantoan, Barbara, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
por: Galimberti, Sara, et al.
Publicado: (2020)

The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia
por: Galimberti, Sara, et al.
Publicado: (2018)

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients
por: Grassi, Susanna, et al.
Publicado: (2020)

A Case of Primary Non-Hodgkin's Lymphoma of the External Auditory Canal
por: Bruschini, Luca, et al.
Publicado: (2013)

Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation
por: Ricci, Federica, et al.
Publicado: (2020)

The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia
por: Guerrini, Francesca, et al.
Publicado: (2016)

Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
por: Mazziotta, Francesco, et al.
Publicado: (2019)

The role of transplantation in Hodgkin lymphoma
por: Maranzano, Michael, et al.
Publicado: (2023)

Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report
por: Carulli, Giovanni, et al.
Publicado: (2011)

Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup
por: Ciabatti, Elena, et al.
Publicado: (2017)

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
por: Beccuti, Marco, et al.
Publicado: (2017)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
por: Renner, Christoph, et al.
Publicado: (2018)

Advances in Hodgkin Lymphoma: Including the Patient’s Voice
por: Smith, Christine Moore, et al.
Publicado: (2022)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020)

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies
por: Dogliotti, Irene, et al.
Publicado: (2018)

The Impact of Protocol Assignment for Older Adolescents with Hodgkin Lymphoma
por: Pieters, Richard S., et al.
Publicado: (2014)

Genetically Determined Height and Risk of Non-hodgkin Lymphoma
por: Moore, Amy, et al.
Publicado: (2020)

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma
por: Lv, Liwei, et al.
Publicado: (2021)

Clinical and Epidemiological Profile of Elderly Hodgkin’s Lymphoma in India
por: Sharma, Manish, et al.
Publicado: (2022)

Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma
por: Gaudel, Pramod, et al.
Publicado: (2022)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

Non-Hodgkin’s Lymphoma: An Unusual Cause of Shoulder Pain
por: Yeak, Raymond D.K., et al.
Publicado: (2023)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease
por: Tavarozzi, Rita, et al.
Publicado: (2021)

Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin’s Lymphoma Cells
por: Kewitz, Stefanie, et al.
Publicado: (2013)

Retroperitoneal extra-adrenal non-Hodgkin lymphoma: An uncommon presentation
por: Ayari, Y., et al.
Publicado: (2018)

Modeling Gene-Environment Interaction for the Risk of Non-hodgkin Lymphoma
por: Zhang, Jiahui, et al.
Publicado: (2019)

Optic Neuritis: A Rare Paraneoplastic Phenomenon of Hodgkin's Lymphoma
por: Khan, Yasir, et al.
Publicado: (2019)

Yescarta: A New Era for Non-Hodgkin Lymphoma Patients
por: AlDallal, Salma M
Publicado: (2020)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qc3ncbimlva91ifm6aor225gh3